Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Queensland Health
Chinese Patent Office
Merck
Federal Trade Commission
Express Scripts

Generated: May 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,028,912

« Back to Dashboard

Which drugs does patent 10,028,912 protect, and when does it expire?

Patent 10,028,912 protects VYXEOS and is included in one NDA.

This patent has seventeen patent family members in eleven countries.

Summary for Patent: 10,028,912
Title:Method of lyophilizing liposomes
Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
Inventor(s): Cabral-Lilly; Donna (Pennington, NJ), Mayer; Lawrence (North Vancouver, CA), Tardi; Paul (Surrey, CA), Watkins; David (East Greenwich, RI), Zeng; Yi (Somerset, NJ)
Assignee: CELATOR PHARMACEUTICALS, INC. (Ewing, NJ)
Application Number:14/352,662
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 10,028,912
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 10,028,912

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401-001 Aug 3, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) ➤ Sign Up
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401-001 Aug 3, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 10,028,912

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2012326370 ➤ Sign Up
Brazil 112014009305 ➤ Sign Up
Canada 2852777 ➤ Sign Up
China 104114156 ➤ Sign Up
China 108853031 ➤ Sign Up
European Patent Office 2768484 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Queensland Health
Daiichi Sankyo
Chubb
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.